Description

Human Albumin Injection provides purified human serum albumin derived from pooled donor plasma, formulated to 20% (w/v), containing 2.5?g albumin per 50?ml. This highly purified protein maintains colloid osmotic pressure and exhibits binding capacity for fatty acids, hormones, drugs, and bilirubin. In research settings, it is used to model fluid volume expansion, hypoalbuminemia, plasma protein binding, osmotic regulation, and passive immunotherapy. Manufactured by Zhengzhou RAAS Blood Products Co., Ltd., under licence S20023023. Each vial is formulated to pH?4 for stability and intended for experimental use only.

Product Specifications

Mechanism of Action & Research Applications

Human Albumin Injection supports passive volume expansion by increasing plasma oncotic pressure and stabilizing fluid distribution. Albumin binds to a variety of molecules—including fatty acids, hormones, bilirubin, and drugs—offering a model for studying protein binding in pharmacokinetics. In laboratory research, this formulation is widely used to simulate restoration of circulating volume, hypoalbuminemia correction, plasma replacement models, and immunoglobulin interactions in cell culture or animal studies, including studies of inflammation, circulatory dynamics, and sepsis. For research use only.

Side Effects (For Reference Only in Models)

Experimental or clinically analogous models may reveal transient reactions such as infusion-related hypotension or hypertension, fluid overload, allergic responses, headache, nausea, or rare renal or thrombotic effects. These outcomes serve as reference data for protocol safety in dose titration and model design.

Disclaimer

Human Albumin Injection is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.